Comparative safety of glucagon like peptide‑1 receptor agonists in patients with type 2 diabetes: a network meta-analysis of cardiovascular outcome trials

Receptor Agonists ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Comparative Safety

Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2019.08.011 ◽

2020 ◽

Vol 44 (1) ◽

pp. 68-77 ◽

Cited By ~ 4

Author(s):

Elodie M. Varin ◽

Brent A. McLean ◽

Julie A. Lovshin

Keyword(s):

Type 2 Diabetes ◽

Adult Patients ◽

Cardiovascular Outcome ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

CARDIOVASCULAR BENEFIT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN FEMALE PATIENTS WITH TYPE 2 DIABETES MELLITUS: A META-ANALYSIS OF RECENT CARDIOVASCULAR OUTCOME TRIALS

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(19)30847-2 ◽

2019 ◽

Vol 73 (9) ◽

pp. 239

Author(s):

David Aguilar ◽

Efstratios Koutroumpakis ◽

Heinrich Taegtmeyer

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Meta Analysis ◽

Cardiovascular Outcome ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Cardiovascular Benefit

Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus

Diabetes Therapy ◽

10.1007/s13300-021-01079-x ◽

2021 ◽

Author(s):

Xiaoling Cai ◽

Linong Ji

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cardiovascular Outcome ◽

Chinese Patients ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Abstract P077: Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Black Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Recent Cardiovascular Outcome Trials

Circulation ◽

10.1161/circ.139.suppl_1.p077 ◽

2019 ◽

Vol 139 (Suppl_1) ◽

Author(s):

Efstratios Koutroumpakis ◽

Heinrich Taegtmeyer ◽

David Aguilar

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Meta Analysis ◽

Cardiovascular Outcome ◽

Black Patients ◽

Glucagon Like Peptide ◽

Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis

BMC Pharmacology and Toxicology ◽

10.1186/s40360-018-0246-x ◽

2018 ◽

Vol 19 (1) ◽

Cited By ~ 6

Author(s):

Xiaowen Zhang ◽

Fei Shao ◽

Lin Zhu ◽

Yuyang Ze ◽

Dalong Zhu ◽

...

Keyword(s):

Type 2 Diabetes ◽

Sequential Analysis ◽

Meta Analysis ◽

Cardiovascular Outcome ◽

Trial Sequential Analysis ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Faculty Opinions recommendation of Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732267672.793559020 ◽

2019 ◽

Author(s):

Mona Momeni

Keyword(s):

Type 2 Diabetes ◽

Meta Analysis ◽

Cardiovascular Outcomes ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Effect of glucagon‐like peptide‐1 receptor agonists in subjects with type 2 diabetes mellitus: a meta‐Analysis

International Journal of Clinical Practice ◽

10.1111/ijcp.14400 ◽

2021 ◽

Author(s):

Weiyun Qian ◽

Fei Liu ◽

Qichao Yang

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Meta Analysis ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Medication adherence to injectable glucagon‐like peptide‐1 (GLP‐1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta‐analysis

International Journal of Clinical Practice ◽

10.1111/ijcp.14060 ◽

2021 ◽

Author(s):

Erin R. Weeda ◽

Alyssa K. Muraoka ◽

Matthew D. Brock ◽

Jessica M. Cannon

Keyword(s):

Type 2 Diabetes ◽

Medication Adherence ◽

Meta Analysis ◽

Once Daily ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)

Current Vascular Pharmacology ◽

10.2174/1570161114666160909161537 ◽

2016 ◽

Vol 14 (5) ◽

pp. 469-473 ◽

Cited By ~ 6

Author(s):

Vasilios G. Athyros ◽

Niki Katsiki ◽

Nikolaos Tentolouris

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Macrovascular Complications ◽

Cardiovascular Outcome ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials

Diabetes & Metabolism Journal ◽

10.4093/dmj.2018.0070 ◽

2019 ◽

Vol 43 (4) ◽

pp. 410 ◽

Cited By ~ 5

Author(s):

Yu Mi Kang ◽

Yun Kyung Cho ◽

Jiwoo Lee ◽

Seung Eun Lee ◽

Woo Je Lee ◽

...

Keyword(s):

Meta Analysis ◽

Cardiovascular Outcome ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Long Acting ◽

Cardiovascular Benefit